Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study.
NCT ID: NCT04378023
Last Updated: 2025-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
34 participants
OBSERVATIONAL
2020-04-24
2027-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary endpoint will be overall survival at 1, 3, and 5 years post-transplant. The secondary endpoints will be: 1) recurrence free survival at 1, 3 and 5 years post-transplant; 2) intention-to-treat survival of overall patients included in the study at 1,3 and 5 year; 3) the rate of patients included in the study who are finally transplanted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Liver Resection Versus Radio-chemotherapy-Transplantation for Hilar Cholangiocarcinoma
NCT02232932
Liver Transplantation for Non-resectable Perihilar Cholangiocarcinoma
NCT04993131
Safety Study of Liver Transplantation for Hilar Cholangiocarcinoma
NCT02178280
Liver Transplantation for Locally Advanced Intrahepatic Cholangiocarcinoma After SIRT and Chemotherapy
NCT06910722
En Bloc Resection of the Liver and Pancreas With a "Non-touch" Technique Followed by Liver Transplantation to Improve the Overall Survival in Patients With Non-resectable Hilar Cholangiocarcinoma Beyond the Mayo Clinic Transplant Criteria
NCT06850753
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The number of subjects necessary is 34 patients to achieve a power of 82% with a significance level of 0.05 to detect a 40% difference between the estimated 50% survival of those patients who are transplanted and 10% of those patients with hCCA unresectable who are not transplanted. This corresponds to a hazard ratio of 3.3219. Estimated loss to follow-up of 10% of patients.
RADIOLOGICAL EVALUATION
It will be considered unresectable those lesions Bismuth IV with the following criteria (Jarnagin WR, et al. Ann Surg 2001; 234:507; Memorial Sloan Kettering Cancer Center Hilar Cholangiocarcinoma Classification):
* Bilateral extension to second order biliary
* Unilateral extension to second-order biliary radicals AND contralateral portal vein involvement OR contralateral hepatic lobar atrophy
* Main or bilateral portal vein involvement
* Insufficient future liver remnant even after portal embolization
It will be performed the tumoral marker (CA 19.9), multiphase chest-abdomen CT scan, magnetic resonance cholangiopancreatography (MRCP) as well as positon emission tomography (PET)-scan if there is doubts of distant disease and upper endoscopic ultrasound (EUS) in order to rule out any obvious lymph node metastases. A biliary drainage will be placed by percutaneous transhepatic biliary drainage (PTBD) or endoscopic biliary drainage (EBD).
NEOADJUVANT TREATMENT
Patients will receive neoadjuvant radiotherapy (External - 50-54 grays) following by concomitant oral capecitabine (1,330mg/m2).Thereafter, gemcitabine iv (1000mg/m2) plus cisplatin iv will be administered the day 1 and 8 every 21 days until transplant.
A staging laparotomy/laparoscopy is recommended before including the patient in waiting list for transplant to confirm the abscence of extra-hepatic disease, especially peritoneal seeding and lymph nodes involvement.
A score exception will be allowed to optimized the treatment received and to be transplanted during the first 6 months.
LIVER TRANSPLANT AND FOLLOW UP
Regarding liver transplant technique, hepatic artery should be avoided for arterial reconstruction using the splenic artery or an iliac conduit.
Biomarker analyses in the explant specimen will be performed.
The patient will be monitored post-operatively at the clinical, biological and morphological levels every 3 months during the first 2 years and every 6 months thereafter in order to detect any recurrence and in the context of standard clinical care.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study group
Patients with unresectable hilar cholangiocarcinoma (hCCA) ≤3cm in radial diameter, without evidence of lymph node or distant metastases
Neoadjuvant Chemo-radiotherapy
Patients will receive neoadjuvant radiotherapy (External - 50-54 grays) following by concomitant oral capecitabine (825mg/m2 bid).Thereafter, gemcitabine iv (1000mg/m2) plus cisplatin iv (25mg/m2) will be administered the day 1 and 8 every 21 days until transplant.
Liver Transplantation
If no spread disease is discovered after neoadjuvant treatment, the patient will be listed for liver transplantation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neoadjuvant Chemo-radiotherapy
Patients will receive neoadjuvant radiotherapy (External - 50-54 grays) following by concomitant oral capecitabine (825mg/m2 bid).Thereafter, gemcitabine iv (1000mg/m2) plus cisplatin iv (25mg/m2) will be administered the day 1 and 8 every 21 days until transplant.
Liver Transplantation
If no spread disease is discovered after neoadjuvant treatment, the patient will be listed for liver transplantation.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≤ 70 years-old
* ECOG 0 or 1
* Unresectable hCCA ≤3cm in radial diameter
Exclusion Criteria
* Liver, extrahepatic or lymph node metastases
* Previous intent of surgical resection or percutaneous biopsy
* Previous or concurrent cancer that is different in primary site or histology from adenocarcinoma, except cervical carcinoma in situ, localized prostate cancer, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis, T1). Any cancer curatively treated 5 years prior to entry is permitted.
* Infection no controlled
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Vall d'Hebron
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cristina Dopazo Taboada
Consultant Surgeon
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cristina Dopazo
Role: PRINCIPAL_INVESTIGATOR
HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA, BARCELONA
Ramón Charco-Torra
Role: PRINCIPAL_INVESTIGATOR
HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA, BARCELONA
Sonia Pascual-Bartolomé
Role: STUDY_CHAIR
HOSPITAL GENERAL UNIVERSITARIO, ALICANTE
Carmelo Loinaz-Segurola
Role: STUDY_CHAIR
HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, MADRID
José María Álamo-Martinez
Role: STUDY_CHAIR
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, SEVILLA
José Luis Lucena de la Poza
Role: STUDY_CHAIR
HOSPITAL UNIVERSITARIO PUERTA DE HIERRO, MAJADAHONDA
Arturo Colon-Rodríguez
Role: STUDY_CHAIR
HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARANON, MADRID
Diego López-Segarra
Role: STUDY_CHAIR
COMPLEJO HOSPITALARIO UNIVERSITARIO, BADAJOZ
Yilliam Fundora-Suárez
Role: STUDY_CHAIR
Hospital Clinic of Barcelona
Andrea Bosca-Robledo
Role: STUDY_CHAIR
Hospital Universitario La Fe
Juan Andrés Echeverri-Cifuentes
Role: STUDY_CHAIR
HOSPITAL UNIVERSITARIO MARQUES DE VALDECILLA, SANTANDER
Marina Vila-Tura
Role: STUDY_CHAIR
HOSPITAL UNIVERSITARIO DE BELLVITGE, BARCELONA
Xavier Merino-Casabiel
Role: STUDY_CHAIR
HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA, BARCELONA
David Leiva-Pedraza
Role: STUDY_CHAIR
HOSPITAL UNIVERSITARIO DE BELLVITGE, BARCELONA
María Teresa Salcedo-Allende
Role: STUDY_CHAIR
HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA, BARCELONA
José Antonio Gracia Solanas
Role: STUDY_CHAIR
HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA, ZARAGOZA
Manuel Angel Barrera-Gómez
Role: STUDY_CHAIR
HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE LA CANDELARIA, TENERIFE
Ricardo Robles-Campos
Role: STUDY_CHAIR
Hospital Universitario Virgen de la Arrixaca
Laura Lladó-Garrida
Role: STUDY_DIRECTOR
HOSPITAL UNIVERSITARIO DE BELLVITGE, BARCELONA
María Teresa Macarulla-Mercadé
Role: STUDY_DIRECTOR
HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA DE BARCELONA
Begoña Navalpotro-Yagüe
Role: STUDY_DIRECTOR
HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA DE BARCELONA
Florian Castet
Role: STUDY_CHAIR
HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA DE BARCELONA
Julio Santoyo
Role: STUDY_CHAIR
HOSPITAL REGIONAL UNIVERSITARIO DE MALAGA
Manuel Durán Martínez
Role: STUDY_CHAIR
HOSPITAL UNIVERSITARIO REINA SOFIA DE CÓRDOBA
Natalia Zambudio
Role: STUDY_CHAIR
Hospital Virgen de las Nieves (Granada)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of HPB Surgery and Transplants, Hospital Vall d´Hebron
Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BS J, Youssef BA M, Klimstra D, Blumgart LH. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9. doi: 10.1097/00000658-200110000-00010.
Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Nyberg SL, Ishitani MB, Rosen CB. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis. 2004 May;24(2):201-7. doi: 10.1055/s-2004-828896.
Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, Gores GJ, Nagorney DM. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005 Sep;242(3):451-8; discussion 458-61. doi: 10.1097/01.sla.0000179678.13285.fa.
Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, Botha JF, Mezrich JD, Chapman WC, Schwartz JJ, Hong JC, Emond JC, Jeon H, Rosen CB, Gores GJ, Heimbach JK. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012 Jul;143(1):88-98.e3; quiz e14. doi: 10.1053/j.gastro.2012.04.008. Epub 2012 Apr 12.
Ethun CG, Lopez-Aguiar AG, Anderson DJ, Adams AB, Fields RC, Doyle MB, Chapman WC, Krasnick BA, Weber SM, Mezrich JD, Salem A, Pawlik TM, Poultsides G, Tran TB, Idrees K, Isom CA, Martin RCG, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Cardona K, Maithel SK. Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease. Ann Surg. 2018 May;267(5):797-805. doi: 10.1097/SLA.0000000000002574.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
hCCA-LT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.